Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ruxolitinib in myeloproliferative neoplasm-associated splanchnic vein thrombosis
2012-002253-30Phase 2Completed
- Sponsor
- Università degli Studi di Firenze
- Start
- Aug 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in myeloproliferative disorder (MPD) and splanchnic vein thrombosis, sponsored by Università degli Studi di Firenze. Primary endpoint: Spleen response by week 24. Started Aug 2012; status: completed.
02
Drugs
03
Conditions
myeloproliferative disorder (MPD)splanchnic vein thrombosis
Beyond the preview
Go deeper on 2012-002253-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002253-30.